A standard treatment for mastocytosis is difficult to apply to individual patients based on the variable clinical course. A general consensus for using antimediator agents such as antihistamines ...

Further injections of the maintenance dose of 100 µg every 4 weeks during the first year, every 6 weeks during the second year and then every 8 weeks if venom immunotherapy is continued for more ...

Additionally, 70 treatment centers were randomly assigned 1:1 to an intervention group or a usual-care group. In the intervention group, the responsible healthcare professionals followed an online ...

The cause or causes of mastocytosis are not fully known, but there's thought to be an association with a change in genes known as the KIT mutation. There's no cure for mastocytosis, so the aim of ...

Systemic mastocytosis (SM) is driven by KIT D816V mutation in approximately 95% of cases. 1 With the emergence of targeted treatments for indolent systemic mastocytosis (ISM) comes an opportunity to ...

The treatment of cutaneous mastocytosis aims at controlling symptoms and preventing mast cell degranulation. Cosmetic treatment includes the use ofPsoralen and ultraviolet A (PUVA) therapy, total skin ...

It can be difficult to receive a diagnosis for a rare disease. As with any other condition, staying informed and working with your healthcare team can help you prepare for whatever ails you.

Oladimeji Ewumi is a freelance health writer and biochemist. He has extensive experience helping brands in the healthcare, biotech, wellness, and medical AI sectors communicate effectively with ...

My goal is to educate consumers with clear, concise, and science-based information on topics that have the potential to impact their well-being and those they care about. Anna Zernone Giorgi is a ...

Ayvakit is a kinase inhibitor approved for the treatment of inoperable or metastatic gastrointestinal stromal tumor (GIST) with specific PDGFRA mutations and for advanced systemic mastocytosis.

The current definition of an immediate hypersensitivity reaction (IHSR) involves anaphylactic type clinical manifestations that occur within the first one (to six) hour(s) after exposure to a trigger.